Compare Smith & Nephew plc (SNN) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Thomson Reuters Corp — how do they compare? Smith & Nephew plc trades at $30.45 (market cap $12.64B), while Thomson Reuters Corp trades at $90.5 (market cap $41.28B). The key difference: Thomson Reuters Corp is far larger — about 3.3× Smith & Nephew plc's market cap, and Thomson Reuters Corp pays the higher dividend (2.75%). Which is the better fit depends on your goals.
| SNN | TRI | |
|---|---|---|
Market Cap | $12.64B | $41.28B |
Sector | Health | Industrials |
52-Week High | $38.70 | $205.54 |
52-Week Low | $28.73 | $76.55 |
Enterprise Value | $15.41B | $43.24B |
Dividend Yield | 2.57% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNN trades at $30.21, down 1.24% today, with a bearish technical signal and mixed earnings history. Revenue grew to $5.81B in 2024 with net income of $412M, while valuation ratios like P/E of 21.25 and P/S of 2.15 suggest moderate pricing. Recent news highlights product launches in robotics and wound care, supporting growth initiatives.
Outlook is cautiously optimistic with strong cash flow and analyst buy ratings at 27%, but risks include earnings misses and rising debt. The stock offers potential from operational improvements, though investor sentiment remains divided amid competitive pressures.
Thomson Reuters (TRI) trades at $90.67, down 5.75% today, with a bullish technical outlook supported by moving averages. The company maintains strong profitability with a 19.93% net margin and 12.63% ROE, though recent earnings showed mixed results with a Q4 2025 miss. Recent developments include a joint venture with KKR for the global print business and strategic AI implementation, positioning TRI for future growth in content and technology services.
Wall Street remains optimistic with a $129.96 consensus price target (43% upside), driven by 51.85% buy ratings. Key risks include execution of AI strategy and competitive pressures. The stock offers value with reasonable valuation multiples (P/E 27.47, P/S 5.49) and consistent dividend payments, making it attractive for long-term investors despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
